Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Todd Riehl | Researchclopedia

Back to researchers

Todd Riehl

50

Works

5,445

Citations

19

h-index

26

i10-index

Research Topics

Lung Cancer Treatments and Mutations Melanoma and MAPK Pathways Colorectal Cancer Treatments and Studies

Affiliations

Roche (Switzerland)2022–2022

The University of Texas MD Anderson Cancer Center2005–2005

Gene Therapy Laboratory2020–2022

Technical University of Munich1991–1991

Top Works

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele,Alexander Drilon,et al.

20191,695 citations

Cancer Genomics and Diagnostics

Lung Cancer Research Studies

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R. Gandara,Sarah Paul,et al.

20181,187 citations

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

Alexander Drilon,Salvatore Siena,et al.

2019523 citations

Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

Eli L. Diamond,Vivek Subbiah,et al.

2017399 citations

Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

Marcia S. Brose,Maria E. Cabanillas,et al.

2016383 citations

BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET Study

Thomas Kaley,Mehdi Touat,et al.

2018324 citations

Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> V600-Mutant Non-Melanoma Cancers

Vivek Subbiah,Igor Puzanov,et al.

2020121 citations

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Solange Peters,Rafał Dziadziuszko,et al.

2022104 citations

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

Susan O’Brien,Farhad Ravandi,et al.

200789 citations